
VANCOUVER — Connectica reporting
HYTN Innovations Inc. and Peptide Development Labs Inc. have finalized their share exchange arrangement and completed a $3M private placement to fund development milestones.
HYTN Innovations Inc. (CSE: HYTN) and Peptide Development Labs Inc. (CSE: PEPT) have closed their previously announced arrangement, effective November 17, 2026. Under the statutory plan of arrangement, HYTN shareholders received new HYTN common shares and PDL common shares, with each HYTN share exchanged for one new HYTN share and 0.0555555555555556 of a PDL share.
Concurrently, PDL completed a non-brokered private placement, raising approximately $3 million through the issuance of 6 million units at $0.50 each. Each unit includes one PDL common share and one-half of a PDL warrant, exercisable at $0.75 for 24 months. The proceeds will support development milestones outlined in HYTN’s management information circular.
The Canadian Securities Exchange granted conditional acceptance of the arrangement on November 11, 2026, with PDL common shares expected to begin trading under the symbol “PEPT” on November 20, 2026. New HYTN common shares will continue trading under the existing ticker “HYTN”.
Registered shareholders must complete and submit a letter of transmittal to receive their new shares and warrants. The arrangement and financing aim to advance HYTN’s product development and PDL’s peptide-based drug candidates, targeting unmet clinical needs in federally regulated markets.
Reported with files from Newswire Canada (via Financial Post).
Connectica provides information only, not financial, investment or legal advice.